Benign prostatic hyperplasia (BPH), and erectile dysfunction drug, Talgentis by Kofikrom Pharmacy Ltd wins pharmaceutical product of the year award
Talgentis Tablet has been honored with the prestigious Premium Pharmaceutical Product of the Year award at the 8th Global Business Brands Summit & Awards. The event, held on Thursday, celebrated the efficacy and innovation behind Talgentis, recognising its impact on medical treatment.
Talgentis Tablets, a phosphodiesterase type 5 (PDE-5) inhibitor, is primarily used in the management of benign prostatic hyperplasia (BPH), erectile dysfunction (ED), and pulmonary hypertension (PH). The medication has gained acclaim for its effectiveness and the advanced technology employed in its development and production.
KofikromPharmacy Ltd are brand owners and Marketing Authorization holders of Talgentis Tablets. Dr. Kofi Addo-Agyekum, Chief Executive Officer and Founder of Kofikrom Pharmacy Ltd. expressed gratitude for the recognition, emphasizing that it serves as both an honor and a challenge to continue innovating in the pharmaceutical field. Dr. Addo-Agyekum hails from three generations of renowned pharmacists known for their sterling contribution to pharmaceutical service in Ghana.
Dr. Addo-Agyekum and his company have won several industry awards so far. The Global Business Brands Summit & Awards, organized by the Entrepreneurs Foundation of Ghana, aims to acknowledge excellence and reward companies and brands for their outstanding performance and significant contributions to their industries and the economy.
The recognition of Talgentis Tablets underscores Kofikrom Pharmacy Ltd.’s commitment to advancing healthcare through innovative pharmaceutical solutions, setting a benchmark for quality and efficacy in the industry.
